Information Mizagliflozin (KWA 0711) Mizagliflozin (KWA 0711) is a novel, potent, selective sodium glucose co-transporter 1 (SGLT1) inhibitor with Ki of 27 nM for human SGLT1. The selectivity ratio (Ki value for human SGLT2/Ki value for human SGLT1) of mizagliflozin is 303. Mizagliflozin shows the potential use for the amelioration of chronic constipation. Targets human SGLT1 (Cell-free assay) 27 nM(Ki) In vitro Mizagliflozin\'s inhibitory activity against SGLTs is evaluated by an in vitro assay of cells transiently expressing SGLTs. Mizagliflozin potently inhibits human SGLT1 in a highly selective manner.. In vivo The oral administration of Mizagliflozin increased fecal wet weight in a dog model of loperamide-induced constipation and a rat model of low-fiber-diet-induced constipation.. Cell Research(from reference) Cell lines：COS-7 cells Concentrations：0-1 μM, 0-30 μM Incubation Time：1 h